Niagen Bioscience, Inc. — Director's Dealing 2013

May 1, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2013-04-25

Reporting Person: Honig Barry C (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-04-25	Common Stock	P	15400	$0.62	Acquired	3290457	Indirect
2013-04-26	Common Stock	P	47900	$0.627	Acquired	3338357	Indirect
2013-04-29	Common Stock	P	26600	$0.633	Acquired	3364957	Indirect
2013-04-29	Common Stock	P	21000	$0.629	Acquired	3385957	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4574959	Direct

Footnotes

F1: Purchase by GRC Consultants, Inc.

F2: Indirect ownership includes, after giving effect to all transactions included in this Form 4, (i) 230,000 Shares owned by GRQ Consultants, Inc. Defined Benefits Plan for the benefit of the Reporting Person; (ii) 962,486 Shares owned by GRQ Consultants, Inc. 401K of which the Reporting Person is the beneficiary; (iii) 2,103,571 Shares owned by GRQ Consultants Inc. Roth 401K FBO Renee Honig, the Reporting Person's spouse, of which the Reporting Person has voting and investment power and disclaims beneficial ownership; and (iv) 89,900 shares Shares owned by GRQ Consultants, Inc., of which the Reporting Person is the President.

F3: Purchased by GRQ Consultants, Inc. 401K.